We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Further evaluation of galliumnitrate to attenuate progression of disease in patients with multiple myeloma is warranted.
2
Agents which have been investigated include galliumnitrate, interferon-alpha and paclitaxel both as single agents and in combination with established cytotoxic drugs.
3
These data suggest that galliumnitrate may have a positive, indirect benefit on survival in myeloma by decreasing the rate of bone resorption.
4
Galliumnitrate was shown in a small, randomized trial to attenuate the rate of bone loss in patients with myeloma treated with chemotherapy.